BEAM - Spark Newswire

1 minute read

Beam Therapeutics Touts Encouraging Preclinical Data From Gene Editing Approach For Hepatitis B Infection

September 19, 11:49 AM

Beam Therapeutics Inc (NASDAQ:BEAM) announced new preclinical data demonstrating the potential of its multiplex base editing approach to reduce hepatitis B…

BEAM

2 minute read

Earnings

Beam Therapeutics Earnings Perspective: Return On Capital Employed

By Benzinga Insights

September 2, 10:28 AM

Benzinga Pro data, Beam Therapeutics (NASDAQ:BEAM) reported Q2 sales of $16.65 million. Earnings fell to a loss of $71.95 million, resulting in a 3.95% decrease from last quarter.

BEAM

7 minute read

Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday

By Lisa Levin

August 29, 2:55 AM

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.

AAPL

7 minute read

This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday

By Lisa Levin

August 17, 5:38 AM

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.

ADES

1 minute read

SVB Leerink Maintains Outperform on Beam Therapeutics, Lowers Price Target to $113

By Benzinga Newsdesk

August 10, 5:50 AM

SVB Leerink analyst Rick Bienkowski maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $118 to $113.

BEAM

4 minute read

Recap Of Monday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 1, 6:41 PM

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application…

AERI

1 minute read

Beam Therapeutics Announces FDA Clinical Hold On BEAM-201 IND Application

By Benzinga Newsdesk

August 1, 6:30 AM

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Friday, July 29, 2022, the company was informed via e-mail communication

BEAM

1 minute read

Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics

By Vandana Singh

July 7, 8:28 AM

Verve Therapeutics Inc (NASDAQ:VERV) entered into an Amended and Restated Collaboration and License Agreement with Beam Therapeutics Inc (NASDAQ:BEAM), which amended…

BEAM

3 minute read

Beam Therapeutics To Present First Research Highlighting Approach To Develop Non-Genotoxic Conditioning Regimens For Patients With Sickle Cell Disease Ahead Of Autologous Transplant

By Benzinga Newsdesk

June 27, 6:32 AM

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company’s internal efforts to develop

BEAM

1 minute read

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

By Vandana Singh

June 17, 2:28 PM

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes…

BEAM

Feed Symbols: BEAM